+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
FEMALE
ID06671262

Comparing Toripalimab With and Without Targeted Radiotherapy in Women With Lymph Node-Positive HRHER2- Breast Cancer

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-11

74

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of combining intensified radiation therapy with neoadjuvant immuno-chemotherapy in patients with lymph node-positive hormone receptor-positivehuman epidermal growth factor receptor 2-negative HRHER2- breast cancer. This study aims to see if adding a focused radiation boost to the tumor can improve the pathologic complete response pCR rate, reduce residual cancer burden RCB, and alter the tumors immune environment compared to previous treatments. The study focuses on high-risk patients who often show resistance to standard chemotherapy. Participants will be randomly assigned to one of three groups one group receives preoperative toripalimab plus chemotherapy without radiation the second group receives toripalimab with stereotactic body radiation therapy SBRT targeting only the primary tumor the third group receives toripalimab with SBRT targeting both the primary tumor and axillary lymph nodes. Radiation doses are given in fractions over 3 to 5 days, followed by chemotherapy cycles combined with toripalimab. After these treatments, all patients undergo surgery to remove the tumor. During the study, researchers will regularly assess treatment effects through pathology and immune measurements, including pCR rates, RCB levels, and tumor-infiltrating lymphocytes TILs. Safety will be monitored weekly for radiation-related side effects. Participants will be followed for up to 4 to 6 months after starting treatment to evaluate outcomes and side effects. This phase 2 trial takes place under medical supervision and aims to provide new insights into combining immunotherapy with radiation for this breast cancer subtype.

CONDITIONS

Brief Title

Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer

Research Team

J

Jian Huang

T

Ting Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here